EpiVax, Inc. - Informatics and Immunology
  • Our Company
    • Company Overview
    • Corporate Responsibility
    • Mission, Vision & Values
    • Team
    • Careers
    • Contact Us
  • Pipeline
    • Pipeline Overview
    • Tregitope: Immunomodulation Power Tool
    • Deimmunization Projects
    • BioDefense Vaccines
  • Immunogenicity Screening
    • Immunogenicity Screening Overview
    • ISPRI Web-based Immunogenicity Screening
    • PreDeFT Analysis
    • JanusMatrix Analysis
    • High Throughput Antibody Immunogenicity Analysis
    • PANDA Screening
    • ISPRI for Host Cell Proteins
    • iVAX: Web-based Vaccine Design
    • PreVAX Analysis
  • Deimmunization
  • Lab Services
    • Lab Services Overview
    • T Cell Assays
    • HLA Binding Assays
    • HLA Transgenic Mice
    • In Vitro Immunization Protocol (IVIP)
  • Press Room
    • Press Room
    • Events
    • Publication & Poster Search
    • Thinking Out Loud (Blog)
  • Contact Us
Select Page
EpiVax and EpiVax Oncology: Ready to Take on Cancer

EpiVax and EpiVax Oncology: Ready to Take on Cancer

by Katie Porter | Aug 22, 2017 | Blog, EpiVax Immunoncology, Featured, News

EpiVax has carved out a niche in the biotech and immunoinformatics industry with our innovative tools and discoveries. Well-situated on a trajectory Dr. De Groot described as “upward and stable,” EpiVax is now gearing up to launch a venture-backed spinoff called...
Optimized H7N9 induces higher Ab in humanized, but not standard, mice

Optimized H7N9 induces higher Ab in humanized, but not standard, mice

by Annie De Groot | May 24, 2017 | Blog, Featured, News

  A new article in Nature Scientific Reports (doi: 10.1038/s41598-017-01372-5) entitled A humanized mouse model identifies key amino acids for low immunogenicity of H7N9 vaccines may explain why H7N9 influenza vaccines are consistently less immunogenic in humans than...
Happy Birthday EpiVax! We’re Celebrating With a New Look!

Happy Birthday EpiVax! We’re Celebrating With a New Look!

by Katie Porter | May 18, 2017 | Blog, Featured, News

Nineteen years ago, on May 18th, 1998, EpiVax incorporated as a biotechnology company. In 2017, our business has never been stronger: the team is stacked with talent, collaborations are abundant and world-wide, and our in silico user base is extensive. We were...
Tregitope Takes a Step Toward the Clinic

Tregitope Takes a Step Toward the Clinic

by Steven Vessella | Apr 25, 2017 | Blog, Featured, News

EpiVax Signs First Commercial License for Tregitope Technology   PROVIDENCE, R.I., April 25, 2017 – Providence-based biotechnology company EpiVax, Inc. (“EpiVax”) has licensed its novel immune-modulating technology to an undisclosed global...
Spring Is Here and EpiVax is Improving Human Health Everywhere

Spring Is Here and EpiVax is Improving Human Health Everywhere

by Katie Porter | Apr 14, 2017 | Events, Featured

Those of us on the U.S. East Coast are happy to say farewell to winter – Spring is Here! And EpiVax is springing up everywhere! Join us at the following events to learn more about immunogenicity, influenza vaccines, personalized cancer vaccines and more!...
BARDA, WHO, CDC and H7N9: Doing the Same Thing All Over Again?

BARDA, WHO, CDC and H7N9: Doing the Same Thing All Over Again?

by Annie De Groot | Mar 7, 2017 | Blog, Featured, News

“Insanity: doing the same thing over and over again and expecting different results.” – Albert Einstein. Due to its high rate of lethality (30-40%) and pandemic potential, H7N9 preparedness has become a priority for public health officials. While...
« Older Entries
Next Entries »

Recent Posts

  • Seoul Immunogenicity and Tolerance Seminar March 4th, 2019
  • BIO Asia March 5th-6th, 2019
  • AsiaTIDES February 26th-28th, 2019
  • European Immunogenicity Platform February 25th-27th, 2019
  • ASM Biothreats January 29th-31st, 2019

Categories

  • Blog
  • EpiVax Immunoncology
  • Events
  • Featured
  • News

Discover

  • Immunogenicity Screening
  • Deimmunization
  • Lab Services
  • Pipeline

About

  • Our Company
  • Press Room
  • Events
  • Publication & Poster Search
  • Thinking Out Loud (Blog)
  • Contact Us

Connect

© 2019 EpiVax, Inc. – Informatics and Immunology, All rights reserved. • 188 Valley Street, Suite 424, Providence, RI 02909 • ph: 401.272.2123 • fax: 401.272.7562